Analysts Set Expectations for Hims & Hers Health, Inc.’s Q2 2024 Earnings (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS) – Equities research analysts at Leerink Partnrs boosted their Q2 2024 earnings estimates for shares of Hims & Hers Health in a report issued on Monday, June 17th. Leerink Partnrs analyst M. Cherny now anticipates that the company will earn $0.06 per share for the quarter, up from their previous estimate of $0.05. Leerink Partnrs has a “Market Perform” rating on the stock. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.18 per share. Leerink Partnrs also issued estimates for Hims & Hers Health’s Q3 2024 earnings at $0.07 EPS and FY2024 earnings at $0.23 EPS.

Several other analysts have also recently issued reports on the stock. Bank of America upped their target price on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company a “buy” rating in a research report on Thursday, June 13th. TheStreet upgraded shares of Hims & Hers Health from a “d” rating to a “c” rating in a research report on Monday, March 4th. Jefferies Financial Group restated a “hold” rating and set a $15.00 target price (down from $17.00) on shares of Hims & Hers Health in a research report on Tuesday, April 16th. Canaccord Genuity Group upped their target price on shares of Hims & Hers Health from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, May 22nd. Finally, Imperial Capital upgraded shares of Hims & Hers Health from an “in-line” rating to an “outperform” rating and set a $16.00 target price on the stock in a research report on Wednesday, February 28th. Seven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $16.43.

Hims & Hers Health Price Performance

HIMS opened at $24.15 on Tuesday. The firm has a 50-day simple moving average of $15.97 and a two-hundred day simple moving average of $12.69. Hims & Hers Health has a 52 week low of $5.65 and a 52 week high of $25.50.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, May 6th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.02 by $0.03. Hims & Hers Health had a negative net margin of 0.24% and a negative return on equity of 0.70%. The business had revenue of $278.20 million for the quarter, compared to analysts’ expectations of $270.37 million. During the same quarter in the previous year, the company earned ($0.05) EPS. The business’s quarterly revenue was up 45.8% compared to the same quarter last year.

Insider Transactions at Hims & Hers Health

In other news, COO Melissa Baird sold 11,750 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $12.08, for a total transaction of $141,940.00. Following the transaction, the chief operating officer now directly owns 538,932 shares of the company’s stock, valued at $6,510,298.56. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, COO Melissa Baird sold 11,750 shares of the stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $12.08, for a total transaction of $141,940.00. Following the transaction, the chief operating officer now directly owns 538,932 shares in the company, valued at $6,510,298.56. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Oluyemi Okupe sold 98,635 shares of the stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $21.42, for a total transaction of $2,112,761.70. Following the transaction, the chief financial officer now owns 146,839 shares in the company, valued at $3,145,291.38. The disclosure for this sale can be found here. Over the last three months, insiders have sold 940,488 shares of company stock valued at $16,026,000. 17.71% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently modified their holdings of HIMS. FNY Investment Advisers LLC acquired a new stake in shares of Hims & Hers Health in the 4th quarter worth $48,000. Belpointe Asset Management LLC acquired a new stake in Hims & Hers Health in the third quarter worth about $76,000. Certuity LLC purchased a new stake in shares of Hims & Hers Health during the fourth quarter worth about $109,000. Corton Capital Inc. acquired a new position in shares of Hims & Hers Health during the third quarter valued at about $122,000. Finally, Custom Index Systems LLC purchased a new position in shares of Hims & Hers Health in the 4th quarter valued at approximately $132,000. 63.52% of the stock is currently owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.